Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2019 Financial Results
TEL AVIV, Israel, Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today provides business update and reports financial results for the three and six months ended June 30, 2019. The Company will host a conference call and webcast at 08:30 ET today.
Financial Summary - Second Quarter 2019 vs. Second Quarter 2018
-- Cash and cash equivalents, short-term deposits and marketable securities
totaled $83.6 million as of June 30, 2019, compared to $90.2 million at
December 31, 2018.
-- Net loss of $4.2 million, or ($0.20) per share, for the three months
ended June 30, 2019, compared to a net loss of $2.7 million, or ($0.17)
per share, for the three months ended June 30, 2018.
-- Research and development expenses amounted to approximately $3.5 million
for the three months ended June 30, 2019, compared to approximately $1.9
million for the three months ended June 30, 2018. The increase resulted
primarily from an increase in clinical and pre-clinical trial expenses.
-- General and administrative expenses amounted to approximately $1.2
million for the three months ended June 30, 2019, compared to
approximately $1.1 million for the three months ended June 30, 2018.
-- Financial expenses amounted to $0.5 million for the three months ended
June 30, 2019, compared to financial income of $0.1 million for the
three months ended June 30, 2018. The increase primarily relates to an
increase in financial income from financial assets.
Conference Call & Webcast:
Monday, August 5(th) @ 8:30am Eastern Time.
Toll Free: 1-877-425-9470
Toll/International: 1-201-389-0878
Israel Toll Free: 1-809-406-247
Conference ID: 13692794
Webcast: http://public.viavid.com/index.php?id=135464
Replay Dial-In Numbers
Toll Free: 1-844-512-2921
Toll/International: 1-412-317-6671
Replay Pin Number: 13692794
Replay Start: Monday August 5, 2019, 11:30 AM ET
Replay Expiry: Monday August 19, 2019, 11:59 PM ET
About Aramchol and Non-alcoholic Steatohepatitis (NASH)
Aramchol (arachidyl amido cholanoic acid) is a novel fatty acid bile acid conjugate, inducing beneficial modulation of intra-hepatic lipid metabolism. Aramchol's ability to modulate hepatic lipid metabolism was discovered and validated in animal models, demonstrating downregulation of the three key pathologies of NASH: steatosis, inflammation and fibrosis. The effect of Aramchol on fibrosis is mediated by downregulation of steatosis and directly on human collagen producing cells. Aramchol has been granted Fast Track designation status by the FDA for the treatment of NASH.
NASH is an emerging world crisis impacting an estimated 3% to 5% of the U.S. population and an estimated 2% to 4% globally. It is the fastest growing cause of liver cancer and liver transplant in the U.S. due to the rise in obesity. NASH is the progressive form of non-alcoholic fatty liver disease that can lead to cardiovascular disease, cirrhosis and liver-related mortality.
About Galmed Pharmaceuticals Ltd.
Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. During 2018, Galmed rannounced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing to initiate a Phase 3/4 clinical study in the third quarter of 2019.
Forward-Looking Statements:
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to Galmed's objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that Galmed intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause Galmed's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the timing and cost of Galmed's planned pivotal Phase 3/4 ARMOR trial, or the ARMOR Study or whether a pivotal trial will be conducted at all; completion and receiving favorable results of the ARMOR Study for Aramchol or any other pre-clinical or clinical trial; regulatory action with respect to Aramchol by the FDA or the EMA; the commercial launch and future sales of Aramchol or any other future products or product candidates; Galmed's ability to comply with all applicable post-market regulatory requirements for Aramchol in the countries in which it seeks to market the product; Galmed's ability to achieve favorable pricing for Aramchol; Galmed's expectations regarding the commercial market for NASH patients; third-party payor reimbursement for Aramchol; Galmed's estimates regarding anticipated capital requirements and Galmed's needs for additional financing; market adoption of Aramchol by physicians and patients; the timing, cost or other aspects of the commercial launch of Aramchol; the development and approval of the use of Aramchol for additional indications or in combination therapy; and Galmed's expectations regarding licensing, acquisitions and strategic operations. More detailed information about the risks and uncertainties affecting Galmed is contained under the heading "Risk Factors" included in Galmed's most recent Annual Report on Form 20-F filed with the SEC on March 13, 2019, and in other filings that Galmed has made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect Galmed's current views with respect to future events, and Galmed does not undertake and specifically disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
GALMED PHARMACEUTICALS LTD.
Consolidated Balance Sheets
---
U.S. Dollars in thousands, except share data and per share data
As of As of
June 30, December 31,
2019 2018
Unaudited Audited
Assets
Current assets
Cash and cash equivalents $
25,778 $
24,159
Short-term deposits 15,282 6,067
Marketable debt securities 42,563 59,962
Other accounts receivable 705 218
Total current assets 84,328 90,406
Right of use assets 603
Property and equipment, net 180 194
Total non-current assets 783 194
Total assets $
85,111 $
90,600
Liabilities and stockholders' equity
Current liabilities
Trade payables $
2,578 $
1,814
Other accounts payable 704 892
Total current liabilities 3,282 2,706
Non-current liabilities
Lease obligation $
442
$
Total non-current liabilities 442
Ordinary shares par value NIS 0.01 per
share; Authorized 50,000,000; Issued
and outstanding: 21,121,337 shares as
of June 30, 2019; 21,018,919 shares
as of December 31, 2018 58 58
Additional paid-in capital 175,424 174,322
Accumulated other comprehensive gain
(loss) 41 (11)
Accumulated deficit (94,136) (86,475)
Total stockholders' equity 81,387 87,894
Total liabilities and stockholders'
equity $
85,111 $
90,600
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Operations (Unaudited)
---
U.S. Dollars in thousands, except share data and per share data
Three months ended Six months ended
June 30, June 30,
2019 2018 2019 2018
Revenue
$ $
270
$ $
538
Research and development
expenses 3,494 1,940 6,763 3,884
General and administrative
expenses 1,207 1,105 1,978 1,988
Total operating expenses 4,701 2,775 8,741 5,334
Financial income, net 532 90 1,080 143
Net loss $
4,169 $
2,685 $
7,661 $
5,191
Basic and diluted net loss
per share $
0.20 $
0.17 $
0.36 $
0.34
Weighted-average number of
shares outstanding used in
computing basic and
diluted net loss per share 21,120,085 15,711,736 21,102,306 15,243,785
GALMED PHARMACEUTICALS LTD.
Consolidated Statements of Cash Flows (Unaudited)
---
U.S. Dollars in thousands
Six months ended
June 30,
2019 2018
Cash flow from operating
activities
Net loss $
(7,661) $
(5,191)
Adjustments required to
reconcile net loss to net cash
used in operating activities
Depreciation and amortization 18 118
Stock-based compensation
expense 1,007 417
Interest income from short-term
deposits (215)
Amortization of discount on
marketable securities (71) (4)
Loss (gain) from realization of
marketable securities (9) 5
Changes in operating assets and
liabilities:
Decrease (increase) in other
accounts receivable (487) (213)
Increase in trade payables 764 70
Increase (decrease) in other
accounts payable (349) 424
Decrease in deferred revenue (538)
Net cash used in operating
activities (7,003) (4,912)
Cash flow from investing
activities
Purchase of property and
equipment (4) (1)
Investment in available for sale
securities (68,717) (85,174)
Investment in short-term
deposits (9,000)
Consideration from sale of
available for sale securities 86,248 3,173
Net cash provided in (used in)
investing activities 8,527 (82,002)
Cash flow from financing
activities
Issuance of ordinary shares and
warrants, net of issuance costs 79,164
Proceeds from exercise of
options 95 880
Net cash provided in financing
activities 95 80,044
Increase (Decrease) in cash and
cash equivalents 1,619 (6,870)
Cash and cash equivalents at the
beginning of the period 24,159 13,021
Cash and cash equivalents at the
end of the period $
25,778 $
6,151
Supplemental disclosure of cash
flow information:
Cash received from interest $
1,057 171
View original content to download multimedia:http://www.prnewswire.com/news-releases/galmed-pharmaceuticals-provides-business-update-and-reports-second-quarter-2019-financial-results-300896220.html
SOURCE Galmed Pharmaceuticals Ltd.
